NL-OMON36041尚未招募不适用
The Trigger of the First Trial Effect: examing pure Sensory Polyneuropathy Patients - FTE in Polyneuropathy Patients
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Symmetric, sensoric, distal polyneuropathy Diabets Mellitus typ I patients defined as: absence of achillestendon reflex, distal ' sock' gnostic sensoric loss.
排除标准
- •- neurological diseases other than proprioceptic loss in the feet, lower legs and hands
- •- orthopedic diseases
- •- vestibular diseases
- •- severe vision disturbances on 1 or 2 eyes (with glasses): vision below 5/60 = able to count the fingers of the examiner at 5 meters distance
- •- other diseases with a potentiel abnormal or disadvantageous effect on the equilibrium
- •- sedic medication
- •- bloodpressure lowering medication
- •- pregnancy
- •- age under 18 years
- •- Body Mass Index above 25kg/m2
研究者
相似试验
已完成
不适用
A Preliminary Trial of the Introduction of Computerised Decision Support to Assist Resuscitation of the Severely Injured in a Level 1 Trauma Centre in IndiaInjuriesACTRN12618001053213Monash University100
招募中
不适用
Examining the cost-effectiveness, acceptability, and efficacy of telehealth physiotherapy on mobility in older people receiving aged care servicesMobilityFallsPhysical Medicine / Rehabilitation - PhysiotherapyInjuries and Accidents - Other injuries and accidentsACTRN12621000734864Concord Repatriation General Hospital240
进行中（未招募）
不适用
IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome(Dose Escalation Study: Varespladib Infusion [A-001] for the Prevention of Acute Chest Syndrome in At-Risk Patients with Sickle Cell Disease and Vaso-occlusive Crisis) - IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest SyndromeAcute Chest Syndrome (ACS) in At-Risk patients with Sickle Cell Disease (SCD) and Vaso-occlusive Crisis (VOC)MedDRA version: 9.1Level: LLTClassification code 10051895Term: Acute chest syndromeEUCTR2007-000969-37-FRAnthera Pharmaceuticals Incorporated75
进行中（未招募）
不适用
IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome(Dose Escalation Study: Varespladib Infusion [A-001] for the Prevention of Acute Chest Syndrome in At-Risk Patients with Sickle Cell Disease and Vaso-occlusive Crisis) - IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest SyndromeEUCTR2007-000969-37-GBAnthera Pharmaceuticals Incorporated75
已完成
1 期
A drug-drug interaction trial between AR882, fluconazole, carbamazepine, celecoxib, and sulfasalazine in healthy particpantsGoutInflammatory and Immune System - Other inflammatory or immune system disordersMusculoskeletal - Other muscular and skeletal disordersACTRN12623001038684Arthrosi Therapeutics Australia Pty, Ltd a subsidiary of Arthrosi Therapeutics, Inc54